Previous Close | 59.42 |
Open | 59.15 |
Volume | 3,311,340 |
Avg. Volume (3M) | 2,554,861 |
Market Cap | 148,550,418,432 |
Price / Earnings (TTM) | 25.00 |
Price / Earnings (Forward) | 11.29 |
Price / Sales | 2.66 |
Price / Book | 1.48 |
52 Weeks Range | |
Earnings Date | 24 Apr 2025 |
TTM Dividend Yield | 6.88% |
Profit Margin | 12.56% |
Operating Margin (TTM) | 13.99% |
Diluted EPS (TTM) | 2.40 |
Quarterly Revenue Growth (YOY) | -3.10% |
Quarterly Earnings Growth (YOY) | 11.50% |
Total Debt/Equity (MRQ) | 23.01% |
Current Ratio (MRQ) | 1.46 |
Operating Cash Flow (TTM) | 9.08 B |
Levered Free Cash Flow (TTM) | -4.94 B |
Return on Assets (TTM) | 4.28% |
Return on Equity (TTM) | 7.30% |
Market Trend
Short Term | Medium Term | ||
Industry | Drug Manufacturers - General (US) | Mixed | Bullish |
Drug Manufacturers - General (Global) | Mixed | Bullish | |
Stock | Sanofi | Bullish | Bullish |
AIStockmoo Score
Analyst Consensus | 1.5 |
Insider Activity | NA |
Price Volatility | -3.0 |
Technical Moving Averages | 2.5 |
Technical Oscillators | -0.5 |
Average | 0.13 |
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue. |
|
Sector | Healthcare |
Industry | Drug Manufacturers - General |
Investment Style | Large Core |
% Held by Institutions | 10.59% |
Ownership
Name | Date | Shares Held |
---|---|---|
Mondrian Investment Partners Ltd | 31 Dec 2024 | 3,453,122 |
52 Weeks Range | ||
Median | 65.00 (9.71%) | |
Total | 1 Hold |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Goldman Sachs | 21 Mar 2025 | 65.00 (9.70%) | Hold | 56.90 |
No data within this time range.
TTM Dividend Yield | 6.88% |
5Y Average Dividend Yield | 4.78% |
Payout Ratio | 85.70% |
Ex Date | Announcement Date | Payment Date | Details |
---|---|---|---|
09 May 2024 | 26 Mar 2024 | 06 Jun 2024 | 2.037356 Cash |
09 May 2024 | 26 Mar 2024 | 06 Jun 2024 | 2.0369079 Cash |
30 May 2023 | - | 23 Jun 2023 | 1.9000852 Cash |
26 May 2022 | - | 27 Jun 2022 | 0.2971788 Cash |
04 May 2022 | 20 Apr 2022 | 31 May 2022 | 1.7967514 Cash |
03 May 2021 | 23 Mar 2021 | 26 May 2021 | 1.906064 Cash |
30 Apr 2020 | 05 Mar 2020 | 26 May 2020 | 1.6993994 Cash |
07 May 2019 | - | 31 May 2019 | 1.722322 Cash |
09 May 2018 | 07 Feb 2018 | 04 Jun 2018 | 1.860874 Cash |
11 May 2017 | 16 Feb 2017 | 07 Jun 2017 | 1.577088 Cash |
05 May 2016 | 19 Feb 2016 | 01 Jun 2016 | 1.630252 Cash |
06 May 2015 | 25 Feb 2015 | 02 Jun 2015 | 1.618087 Cash |
17 May 2010 | 12 Feb 2010 | 14 Jun 2010 | 1.62732 Cash |
04 Jun 2007 | 05 Mar 2007 | 03 Jul 2007 | 1.14537 Cash |
02 Jun 2006 | 06 Mar 2006 | 03 Jul 2006 | 0.912 Cash |
02 Jun 2005 | 01 Mar 2005 | 01 Jul 2005 | 0.7993 Cash |
Show more |
Annual Dividend Yield
Year | Annual Dividend ($) | Frequency/Year | Yield % |
---|---|---|---|
2024 | 4.07 | 2 | 8.45 |
2023 | 1.90 | 1 | 3.82 |
2022 | 2.09 | 2 | 4.32 |
2021 | 1.91 | 1 | 3.81 |
2020 | 1.70 | 1 | 3.50 |
2019 | 1.72 | 1 | 3.43 |
2018 | 1.86 | 1 | 4.29 |
2017 | 1.58 | 1 | 3.67 |
2016 | 1.63 | 1 | 4.03 |
2015 | 1.62 | 1 | 3.79 |
2010 | 1.63 | 1 | 5.05 |
2007 | 1.15 | 1 | 2.52 |
2006 | 0.912 | 1 | 1.98 |
2005 | 0.799 | 1 | 1.82 |
Show more |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |